TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00418288
Drug: glucagon-like-peptide-1
Normalized name: Glucagon-like-peptide-1 (7-36) amide
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous infusion of 1.2pmol/kg/min for 7 hours
Study: NCT00743886
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of 6 cc of saline into injured area
Study: NCT04178590
Drug: SRP + Injectable Platelet-Rich Fibrin
Normalized name: platelet glycoprotein VI
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
Study: NCT02432807
Drug: Vancomycin 1.1%
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin hydrochloride ophthalmic ointment 1.1%
Study: NCT00430807
Drug: hydroxychloroquine/placebo
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02912663
Drug: Verapamil and Magnesium Sulfate
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose strategy will be used
Study: NCT01283256
Drug: zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: zonisamide 100mg tablets
Study: NCT01324830
Drug: day 1 to day 14
Normalized name: seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low to high dose
Study: NCT00384956
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02760251
Drug: romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00251602
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
Study: NCT00251602
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
Study: NCT00003029
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00364793
Drug: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Normalized name: efavirenz / emtricitabine / tenofovir disoproxil
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)
Study: NCT01455350
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of daily topical 5% lidocaine application
Study: NCT01128712
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg /day
Study: NCT01128712
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 450 mg/day
Study: NCT01209858
Drug: Perampanel and Microgynon-30
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
Study: NCT01209858
Drug: Perampanel and Microgynon-30
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
Study: NCT03288298
Drug: luteolin
Normalized name: 3'-o-methylluteolin
DrugBank: Luteolin (DB15584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flavonoid natural extract
Study: NCT03288298
Drug: nano-luteolin
DrugBank: Luteolin (DB15584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nanoparticles of luteolin
Study: NCT02278601
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study: NCT02582905
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
Study: NCT01494779
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous dose of 5mg
Study: NCT01835782
Drug: L-Serine
Normalized name: L-Serine
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01094275
Drug: Clopidogrel 75mg, Omeprazole 20mg
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clopidogrel and or Omeprazole as applicable
Study: NCT00602303
Drug: Torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01256541
Drug: Kristalose
Normalized name: Kristalose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
Study: NCT00036335
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00333996
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00485108
Drug: Artificial Tears (Methyl cellulose drops)
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Study: NCT00677339
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 6g orally daily
Study: NCT00677339
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50000 IU once monthly orally
Study: NCT00677339
Drug: Placebo Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo vitamin D orally once monthly
Study: NCT04028388
Drug: Docetaxel in Parenteral Dosage Form
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
Study: NCT00917059
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose of 10 mg per day
Study: NCT00917059
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose of 150 mg per day
Study: NCT02430077
Drug: Obeticholic Acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
Study: NCT03313596
Drug: ADV-Tk
Normalized name: ADV-TK
DrugBank: Aglatimagene besadenovec (DB15074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
Study: NCT00917592
Drug: amoxicillin plus clavulanic acid
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
Study: NCT00917592
Drug: amoxicillin plus clavulanic acid
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
Study: NCT04076826
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
Study: NCT04076826
Drug: Propofol or Midazolam
Normalized name: Propofol
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
Study: NCT03698734
Drug: Evening primrose oil(EPO)
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
Study: NCT02663128
Drug: Lanabecestat
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01812044
Drug: subtenons anesthetic - preservative-free bupivacaine 0.75%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01812044
Drug: topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005104
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005104
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00624130
Drug: Yasmin 20
Normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
Study: NCT01812044
Drug: topical control - 0.5 cc of Hypromellose 0.3% gel
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02720484
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00624130
Drug: Mercilon
Normalized name: DESOGESTREL 0.15 mg / ETHINYL ESTRADIOL 0.02 mg ORAL TABLET [MERCILON]
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Study: NCT02086227
Drug: Glucagon for Injection (Fresenius Kabi USA)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
Study: NCT02086227
Drug: Glucagon for Injection (Bedford Laboratories)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
Study: NCT00645086
Drug: clarithromycin extended-release tablets
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
Study: NCT03420638
Drug: Adjunct Exparel (bupivacaine liposome suspension 1.3%)
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
Study: NCT00041314
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00041314
Drug: exisulind
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00041314
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00184587
Drug: candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02490657
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb.
Study: NCT02490657
Drug: normal saline (Saline 0.9%)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02547623
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: depot intracameral
Study: NCT00826514
Drug: Tanezumab
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, 20 mg, single dose.
Study: NCT03756090
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
Study: NCT03756090
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study: NCT03756090
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
Study: NCT01071070
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
Study: NCT00021294
Drug: eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021294
Drug: triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03812510
Drug: A-101
Normalized name: YA-101
DrugBank: P-BCMA-101 (DB17371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrogen peroxide topical solution 45%
Study: NCT00249145
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02286882
Drug: PF-06409577 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Study: NCT04130815
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
Study: NCT00146042
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00146042
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02909153
Drug: Triferic
Normalized name: Triferic
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
Study: NCT03040024
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Study: NCT00635622
Drug: LACTIN-V
Normalized name: Lactin-V
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Study: NCT01133743
Drug: Lenalidomide and Dexamethasone
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
Study: NCT01220219
Drug: Pregabalin controlled release, 82.5 mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
Study: NCT01220219
Drug: Pregabalin controlled release, 165 mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 165 mg controlled release tablet administered once daily for four days.
Study: NCT01220219
Drug: Pregabalin immediate release, 75mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg immediate release capsule administered every 12 hours for four days
Study: NCT01027689
Drug: alprazolam commercial immediate release oral tablet
Normalized name: alprazolam Extended Release Oral Tablet
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablet, single dose
Study: NCT01027689
Drug: alprazolam test sublingual tablet
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablet, single dose
Study: NCT00975663
Drug: Tacrolimus and MMF
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
Study: NCT01118910
Drug: Vusion
Normalized name: Vusion
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vusion will be applied to areas of intertrigo
Study: NCT00219908
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00519077
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
Study: NCT00927485
Drug: Calcumin (Curcumin)
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
Study: NCT02039947
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules
Study: NCT02039947
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets
Study: NCT00349128
Drug: fenofibrate and metformin combination (drug)
Normalized name: simvastatin and fenofibrate
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02646904
Drug: Nasal Beclomethasone Dipropionate
Normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
Study: NCT00257036
Drug: levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no